BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Hansoh Pharmaceutical Group readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Hansoh Pharmaceutical Group's dru
 gs run\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07765628-1807@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:HS-20118: Phase 2 readout est. (NCT07765628)
DESCRIPTION:HS-20118\, phase 2\, Psoriasis.\nStudy: A Phase 2 Study of HS-2
 0118 to Evaluate the Efficacy and Safety in Participant With Moderate-to-S
 evere Plaque Psoriasis\nEstimated primary completion: 28 February 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/hs-20118#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07765628
URL:https://assetmemo.bio/drug/hs-20118#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07879885-1951@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:HS-20137: Phase 2 readout est. (NCT07879885)
DESCRIPTION:HS-20137\, phase 2\, Psoriasis.\nStudy: An Open-label Study of 
 HS-20137 in Participants With Moderate-to-Severe Plaque Psoriasis\nEstimat
 ed primary completion: 1 March 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/hs-20137#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07879885
URL:https://assetmemo.bio/drug/hs-20137#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07156500-144@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20270330
DTEND;VALUE=DATE:20270331
SUMMARY:olatorepatide: Phase 3 readout est. (NCT07156500)
DESCRIPTION:olatorepatide\, phase 3\, Type 2 Diabetes.\nStudy: A Phase 3 St
 udy of HS-20094 in Patients With T2DM Inadequately Controlled With Diet an
 d Exercise Alone\nEstimated primary completion: 30 March 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/olatorepatide#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07156500
URL:https://assetmemo.bio/drug/olatorepatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07156539-144@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20270330
DTEND;VALUE=DATE:20270331
SUMMARY:olatorepatide: Phase 3 readout est. (NCT07156539)
DESCRIPTION:olatorepatide\, phase 3\, Type 2 Diabetes.\nStudy: A Phase 3 St
 udy of HS-20094 in Patients With T2DM\nEstimated primary completion: 30 Ma
 rch 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/olatorepati
 de#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7156539
URL:https://assetmemo.bio/drug/olatorepatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06844799-1951@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:HS-20137: Phase 3 readout est. (NCT06844799)
DESCRIPTION:HS-20137\, phase 3\, Psoriasis.\nStudy: A Study of HS-20137 in 
 Participants with Moderate-to-severe Plaque Psoriasis\nEstimated primary c
 ompletion: 31 March 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/hs-20137#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT06844799
URL:https://assetmemo.bio/drug/hs-20137#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05549258-5632@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20270413
DTEND;VALUE=DATE:20270414
SUMMARY:Inebilizumab: Phase 2 readout est. (NCT05549258)
DESCRIPTION:Inebilizumab\, phase 2.\nStudy: Study of Inebilizumab in Pediat
 ric Subjects With Neuromyelitis Optica Spectrum Disorder\nEstimated primar
 y completion: 13 April 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/inebilizumab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT05549258
URL:https://assetmemo.bio/drug/inebilizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07602777-2501@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20271105
DTEND;VALUE=DATE:20271106
SUMMARY:Risvutatug rezetecan: Phase 1/2 readout est. (NCT07602777)
DESCRIPTION:Risvutatug rezetecan\, phase 1/2.\nStudy: A Study Evaluating th
 e Efficacy and Safety of Risvutatug Rezetecan in Participants With Advance
 d Sarcomas (EMBOLD Sarcoma-202)\nEstimated primary completion: 5 November 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/risvutatug-reze
 tecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07602777
URL:https://assetmemo.bio/drug/risvutatug-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07099898-2501@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20271105
DTEND;VALUE=DATE:20271106
SUMMARY:Risvutatug rezetecan: Phase 3 readout est. (NCT07099898)
DESCRIPTION:Risvutatug rezetecan\, phase 3\, Small Cell Lung Cancer.\nStudy
 : A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Canc
 er (SCLC) [EMBOLD SCLC-301]\nEstimated primary completion: 5 November 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/risvutatug-rezeteca
 n#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 099898
URL:https://assetmemo.bio/drug/risvutatug-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07555054-931@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20271111
DTEND;VALUE=DATE:20271112
SUMMARY:HS-10390: Phase 2 readout est. (NCT07555054)
DESCRIPTION:HS-10390\, phase 2\, Chronic Kidney Disease.\nStudy: A Study of
  the Effect and Safety of HS-10390 in the Treatment of Participants With C
 hronic Kidney Disease\nEstimated primary completion: 11 November 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/hs-10390#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07555054
URL:https://assetmemo.bio/drug/hs-10390#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06526624-2501@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Risvutatug rezetecan: Phase 3 readout est. (NCT06526624)
DESCRIPTION:Risvutatug rezetecan\, phase 3\, Small Cell Lung Cancer.\nStudy
 : A Study of HS-20093 vs Active Surveillance in Limited-Stage Small Cell L
 ung Cancer\nEstimated primary completion: 30 November 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/risvutatug-rezetecan#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06526624
URL:https://assetmemo.bio/drug/risvutatug-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07685808-144@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20280121
DTEND;VALUE=DATE:20280122
SUMMARY:olatorepatide: Phase 2 readout est. (NCT07685808)
DESCRIPTION:olatorepatide\, phase 2\, Obesity.\nStudy: Study of Olatorepati
 de in Adult Participants Living With Overweight or Obesity Without Diabete
 s\nEstimated primary completion: 21 January 2028. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/olatorepatide#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07685808
URL:https://assetmemo.bio/drug/olatorepatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07824882-2501@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20280330
DTEND;VALUE=DATE:20280331
SUMMARY:Risvutatug rezetecan: Phase 2 readout est. (NCT07824882)
DESCRIPTION:Risvutatug rezetecan\, phase 2\, Non-Small Cell Lung Cancer.\nS
 tudy: A Phase II Study of HS-20093 Injection Combined With Adebrelimab Ver
 sus HS-20093 Injection in Previously Treated Patients With Advanced or Met
 astatic Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic
  Alterations\nEstimated primary completion: 30 March 2028. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/risvutatug-rezetecan#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07824882
URL:https://assetmemo.bio/drug/risvutatug-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07759869-9280@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:HS-10380: Phase 3 readout est. (NCT07759869)
DESCRIPTION:HS-10380\, phase 3\, Schizophrenia.\nStudy: A Study to Evaluate
  the Long-term Safety of HS-10380 in Patients With Schizophrenia\nEstimate
 d primary completion: 31 July 2028. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/hs-10380#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07759869
URL:https://assetmemo.bio/drug/hs-10380#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06570798-5632@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20280806
DTEND;VALUE=DATE:20280807
SUMMARY:Inebilizumab: Phase 2 readout est. (NCT06570798)
DESCRIPTION:Inebilizumab\, phase 2\, Systemic Lupus Erythematosus.\nStudy: 
 A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoi
 mmune Diseases\nEstimated primary completion: 6 August 2028. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/inebilizumab#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT06570798
URL:https://assetmemo.bio/drug/inebilizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07830329-144@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20281124
DTEND;VALUE=DATE:20281125
SUMMARY:olatorepatide: Phase 2 readout est. (NCT07830329)
DESCRIPTION:olatorepatide\, phase 2\, Obesity.\nStudy: Efficacy and Safety 
 of Olatorepatide Versus Placebo in Adults With Moderate to Severe Hidraden
 itis Suppurativa Living With Overweight or Obesity\nEstimated primary comp
 letion: 24 November 2028. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/olatorepatide#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07830329
URL:https://assetmemo.bio/drug/olatorepatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07896265-144@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20281219
DTEND;VALUE=DATE:20281220
SUMMARY:olatorepatide: Phase 3 readout est. (NCT07896265)
DESCRIPTION:olatorepatide\, phase 3\, Obesity.\nStudy: Efficacy And Safety 
 of Olatorepatide in Adults With Overweight or Obesity Without Diabetes\nEs
 timated primary completion: 19 December 2028. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/olatorepatide#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07896265
URL:https://assetmemo.bio/drug/olatorepatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07464327-2501@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Risvutatug rezetecan: Phase 3 readout est. (NCT07464327)
DESCRIPTION:Risvutatug rezetecan\, phase 3\, Non-Small Cell Lung Cancer.\nS
 tudy: A Phase III Study of HS-20093 Injection Combined With Adebrelimab Ve
 rsus Docetaxel in Previously Treated Patients With Advanced or Metastatic 
 Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterat
 ions\nEstimated primary completion: 31 December 2028. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/risvutatug-rezetecan#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07464327
URL:https://assetmemo.bio/drug/risvutatug-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06885034-2501@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20290109
DTEND;VALUE=DATE:20290110
SUMMARY:Risvutatug rezetecan: Phase 1/2 readout est. (NCT06885034)
DESCRIPTION:Risvutatug rezetecan\, phase 1/2.\nStudy: A Study to Test the S
 afety and Effectiveness of GSK5764227\, Alone or With Other Treatments\, i
 n Participants With Advanced Gastrointestinal Cancers That Cannot be Surgi
 cally Removed (EMBOLD PanGI-201)\nEstimated primary completion: 9 January 
 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/risvutatug-reze
 tecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT06885034
URL:https://assetmemo.bio/drug/risvutatug-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07911787-9280@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20290124
DTEND;VALUE=DATE:20290125
SUMMARY:HS-10380: Phase 3 readout est. (NCT07911787)
DESCRIPTION:HS-10380\, phase 3\, Schizophrenia.\nStudy: Phase 3 Study of HS
 -10380 for Acute Schizophrenia in Chinese Adults\nEstimated primary comple
 tion: 24 January 2029. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/hs-10380#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07911787
URL:https://assetmemo.bio/drug/hs-10380#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07602855-2501@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20290622
DTEND;VALUE=DATE:20290623
SUMMARY:Risvutatug rezetecan: Phase 1/2 readout est. (NCT07602855)
DESCRIPTION:Risvutatug rezetecan\, phase 1/2.\nStudy: A Study of Risvutatug
  Rezetecan in Combination With Ivonescimab in Participants With Advanced S
 olid Tumors (EMBOLD PanTumour-103)\nEstimated primary completion: 22 June 
 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/risvutatug-reze
 tecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07602855
URL:https://assetmemo.bio/drug/risvutatug-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07802704-2501@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20291205
DTEND;VALUE=DATE:20291206
SUMMARY:Risvutatug rezetecan: Phase 3 readout est. (NCT07802704)
DESCRIPTION:Risvutatug rezetecan\, phase 3.\nStudy: A Study of Risvutatug R
 ezetecan in Participants With Metastatic Castration-resistant Prostate Can
 cer (mCRPC) [EMBOLD Prostate-302]\nEstimated primary completion: 5 Decembe
 r 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/risvutatug-re
 zetecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07802704
URL:https://assetmemo.bio/drug/risvutatug-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06987539-5632@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20300313
DTEND;VALUE=DATE:20300314
SUMMARY:Inebilizumab: Phase 2 readout est. (NCT06987539)
DESCRIPTION:Inebilizumab\, phase 2\, Generalized Myasthenia Gravis.\nStudy:
  A Study to Evaluate the Pharmacokinetics\, Pharmacodynamics\, Safety and 
 Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravi
 s (gMG)\nEstimated primary completion: 13 March 2030. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/inebilizumab#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT06987539
URL:https://assetmemo.bio/drug/inebilizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07621601-2501@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Risvutatug rezetecan: Phase 3 readout est. (NCT07621601)
DESCRIPTION:Risvutatug rezetecan\, phase 3\, Esophageal Squamous Cell Carci
 noma.\nStudy: A Study of HS-20093 in Patients With Pretreated Advanced or 
 Metastatic Esophageal Squamous Cell Carcinoma (ESCC)\nEstimated primary co
 mpletion: 31 December 2030. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/risvutatug-rezetecan#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07621601
URL:https://assetmemo.bio/drug/risvutatug-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07222553-5632@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20310610
DTEND;VALUE=DATE:20310611
SUMMARY:Inebilizumab: Phase 2 readout est. (NCT07222553)
DESCRIPTION:Inebilizumab\, phase 2.\nStudy: Study to Evaluate the Pharmacok
 inetics\, Pharmacodynamics\, Safety\, and Tolerability of Inebilizumab in 
 Pediatric Participants With IgG4-RD\nEstimated primary completion: 10 June
  2031. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/inebilizumab#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07222
 553
URL:https://assetmemo.bio/drug/inebilizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07598825-5632@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20310730
DTEND;VALUE=DATE:20310731
SUMMARY:Inebilizumab: Phase 3 readout est. (NCT07598825)
DESCRIPTION:Inebilizumab\, phase 3.\nStudy: A Trial of Inebilizumab in Part
 icipants With Autoimmune Hepatitis\nEstimated primary completion: 30 July 
 2031. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/inebilizumab#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT075988
 25
URL:https://assetmemo.bio/drug/inebilizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07851220-5632@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20310927
DTEND;VALUE=DATE:20310928
SUMMARY:Inebilizumab: Phase 3 readout est. (NCT07851220)
DESCRIPTION:Inebilizumab\, phase 3.\nStudy: A Phase 3 Study of Inebilizumab
  in Participants With Primary Membranous Nephropathy\nEstimated primary co
 mpletion: 27 September 2031. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/inebilizumab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07851220
URL:https://assetmemo.bio/drug/inebilizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
